Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
IPO Year: 1980
Exchange: NYSE
Website: bio-rad.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2024 | $350.00 → $400.00 | Neutral → Buy | Citigroup |
| 8/28/2024 | $340.00 | Equal Weight | Wells Fargo |
| 6/3/2024 | $315.00 | Hold | Jefferies |
| 4/3/2024 | $400.00 → $365.00 | Buy → Neutral | Citigroup |
| 12/7/2023 | $395.00 | Buy | UBS |
| 6/16/2023 | $550.00 | Overweight | Wells Fargo |
| 12/7/2022 | $565.00 | Outperform | RBC Capital Mkts |
| 8/25/2022 | $715.00 | Outperform | Credit Suisse |
| 1/28/2022 | $915.00 → $750.00 | Buy | Citigroup |
| 7/30/2021 | $735.00 → $930.00 | Overweight | Wells Fargo |
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Operating Officer Jon DiVincenzo will host one-on-one meetings with investors during the Jefferies Global Healthcare Conference in New York City, on June 4, 2025. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and $2.6 billion in reve
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 PM Eastern Time (10:35 AM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at bio-rad.com. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "We navigated a highly dynamic first quarter that became progressively more challenging, yet we delivered solid margins through focused execution and careful expense management. Given the current levels of market uncertainty, we are moderating our full-year 2025 outlook to reflect the evolving macro environment. Going forward, we remain committed to advancing our growth and margin expansion initiatives." Financial Results Highl
LOUISVILLE, Colo. and HERCULES, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc (NASDAQ:BDSX), a leading diagnostics solutions company, and Bio-Rad Laboratories (NYSE:BIO), a global leader in life science research and diagnostics products, contributed to new research findings from Friends of Cancer Research's (Friends') ctMoniTR Project, recently published in Clinical Cancer Research (CCR). The findings demonstrate a strong association between changes in levels of circulating tumor DNA (ctDNA) and treatment outcomes, offering the potential for integration of ctDNA analysis in therapeutic development programs, and clinical cancer care. The ctMoniTR Project (ctDNA to Monitor Treatm
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2025 on Thursday, May 1, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:30 PM Pacific Time (5:30 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available
Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July 2024Signed strategic partner and investor, Bio-Rad LaboratoriesFully funded clinical kitted product development with $50+ million in equity raisesAdvanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the
NEW YORK, March 17, 2025 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, March 21, 2025, the Index will be rebalanced, and the following changes will be effective. Action Company Name Ticker Symbol Addition Bio-Rad Labs A BIO Addition FMC Corp FMC Addition Juniper Networks JNPR Addition PayPal Holdings PYPL Deletion Hewlett Packard Enterprise Company
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2024. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, commented: "Bio-Rad demonstrated resilience and adaptability in 2024. While the biopharma headwinds dampened our Life Science segment results, our Clinical Diagnostics business returned to a more normalized growth rate, and our ongoing transformation initiatives and diligent cost management helped improve our gross margins." Mr. Schwartz continued: "We begin 2025 in a strong position and remain committed to advancing
Transaction To Complement Bio-Rad's Existing Digital PCR Portfolio and Accelerate Development of Next-Generation Digital PCR Solutions Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a binding offer to purchase all equity interests in Stilla Technologies ("Stilla"). The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025. With operations in France and the U.S., Stilla develops and markets next-generation digital PCR
Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial LaunchStrategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering ("Registered Direct Offering") and concurrent private placement ("PIPE Offering"). The Company's five largest shareholders, including Bio-Rad Laboratories, Inc., (NYSE:BIO) ("Bio-Rad"), a key strategic partner of the Company, led the funding round. The round is expected
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring. Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company's several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health D
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju will join the company as its new Executive Vice President and Chief Financial Officer, effective April 15, 2024. Mr. Lakkaraju joins Bio-Rad from Benchmark Electronics, a multi-national leader in electronics manufacturing services, where he served as Executive Vice President and Chief Financial Officer responsible for all finance-related functions supporting the company's global operations since 2018. Prior to Benchmark, he held Chief Financial Officer and senior operational roles at several large, multinational companies including Suppo
Life sciences tools veteran brings decades of experience leading successful teams, commercializing industry-defining technology platforms, and scaling global organizations Resolve Biosciences, a company pioneering Molecular Cartography™ technology, announced today that it has appointed John Stark as Chief Executive Officer. As part of this transition, Resolve Biosciences' previous CEO, Jason Gammack, will be leaving the company. Mr. Stark brings more than 20 years of experience commercializing early-stage technologies, scaling organizations, and navigating capital markets for some of the most innovative life sciences companies. Most recently, Mr. Stark was Chief Executive Officer of Quant
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader of life science research and clinical diagnostic products, today announced the appointment of Simon May as Executive Vice President and President of the Life Science Group, effective January 4, 2022. He succeeds Annette Tumolo who will retire from this role at that time. Dr. May will be responsible for providing leadership and management of the overall strategy and business direction for the company's Life Science Group global operations. "We are pleased to promote Simon and believe that his strong experience and expertise, coupled with his strengths in building high-performing teams at Bio-Rad, make him ideally suited for this importa
SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)
SC 13G - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)
3 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
10-Q - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
10-Q - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
SD - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
10-Q - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
DEF 14A - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "We navigated a highly dynamic first quarter that became progressively more challenging, yet we delivered solid margins through focused execution and careful expense management. Given the current levels of market uncertainty, we are moderating our full-year 2025 outlook to reflect the evolving macro environment. Going forward, we remain committed to advancing our growth and margin expansion initiatives." Financial Results Highl
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2025 on Thursday, May 1, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:30 PM Pacific Time (5:30 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2024. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, commented: "Bio-Rad demonstrated resilience and adaptability in 2024. While the biopharma headwinds dampened our Life Science segment results, our Clinical Diagnostics business returned to a more normalized growth rate, and our ongoing transformation initiatives and diligent cost management helped improve our gross margins." Mr. Schwartz continued: "We begin 2025 in a strong position and remain committed to advancing
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year of 2024 on Thursday, February 13, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast wi
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024. Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 percent compared to $632.1 million reported for the third quarter of 2023. On a currency-neutral basis, quarterly sales increased 3.4 percent compared to the same period in 2023. The increase in net sales was driven by higher sales in our Clinical Diagnostics segment. Life Science segment net sales for the third quarter were $260.9 million, a decrease of 1.0 percent compared to the same period in 2023. On a currency-neutr
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 800-579-2543 within the U.S. or 785-424-1789 outside the U.S., access code: BIORAD. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for u
Interest in kidney transplant assay represents approximately 25% of US transplant volumeCompany lays out land and expand strategy in transplant IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders,We are thrilled to report that we have successfully launched GraftAssure™, which is our research-use-only assay that can detect early evidence of graft organ damage in a patient's blood. On July 11, 2024, our GraftAssure assay was run at a major metropolitan transplant center and research university in the northeast United State
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2024. Second-quarter 2024 total net sales were $638.5 million, a decrease of 6.3 percent compared to $681.1 million reported for the second quarter of 2023. On a currency-neutral basis, quarterly sales decreased 5.4 percent compared to the same period in 2023. Life Science segment net sales for the second quarter were $250.5 million, a decrease of 16.5 percent compared to the same period in 2023. On a currency-neutral basis, Life Science segment sales decreased by 15.9 percent compared to the same quart
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2024 on Thursday, August 1, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 800-343-4849 within the U.S. or 203-518-9856 outside the U.S., access code: BIORAD. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024. First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023. On a currency-neutral basis, quarterly sales decreased 9.6 percent compared to the same period in 2023. Life Science segment net sales for the first quarter were $241.7 million, a decrease of 25.3 percent compared to the same period in 2023. On a currency-neutral basis, Life Science segment sales decreased by 25.2 percent compared to the same quarter
Citigroup upgraded Bio-Rad Labs from Neutral to Buy and set a new price target of $400.00 from $350.00 previously
Wells Fargo initiated coverage of Bio-Rad Labs with a rating of Equal Weight and set a new price target of $340.00
Jefferies resumed coverage of Bio-Rad Labs with a rating of Hold and set a new price target of $315.00
Citigroup downgraded Bio-Rad Labs from Buy to Neutral and set a new price target of $365.00 from $400.00 previously
UBS initiated coverage of Bio-Rad Labs with a rating of Buy and set a new price target of $395.00
Wells Fargo initiated coverage of Bio-Rad Labs with a rating of Overweight and set a new price target of $550.00
RBC Capital Mkts initiated coverage of Bio-Rad Labs with a rating of Outperform and set a new price target of $565.00
Credit Suisse initiated coverage of Bio-Rad Labs with a rating of Outperform and set a new price target of $715.00
Citigroup reiterated coverage of Bio-Rad Labs with a rating of Buy and set a new price target of $750.00 from $915.00 previously
Wells Fargo reiterated coverage of Bio-Rad Laboratories with a rating of Overweight and set a new price target of $930.00 from $735.00 previously